The Latest Breaking News from FDA

The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age.  Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA…

Here's a roundup of top developments in the biotech space over the last 24 hours:

U.S. regulators have authorized the first COVID-19 shots for infants and preschoolers

Whether or not you’ve heard of the chemical bisphenol A, better known as BPA, studies show that it’s almost certainly in your body. BPA is used in the manufacturing of products like plastic water bottles, baby bottles, toys and food packaging, including in the lining of cans.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners for a total investment of $100 million.  Rhythm intends to use the proceeds to support global commercialization efforts for its newly approved Imcivree (setmelanotide) and ongoing clinical development. With this new approval, Imcivree is indicated for chronic weight management…

One and a half years after the adult COVID-19 vaccine, a kids' shot is here. This is why it took so much longer

Gov. Ron DeSantis on Thursday defended the state’s decision not to preorder COVID-19 pediatric vaccines for children under 5, saying that parents who want the shots can access them without the state’s help.

The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).

After US regulators took a major step towards approving COVID-19 vaccines for kids under five, here's what you need to know about the possibility of something similar happening in Australia.